Allogeneic peripheral stem cell transplantation in six children with non-malignant hematologic or metabolic diseases which are eventually fatal was carried out with parental donors. Given three to five HLA mismatches, all grafts underwent CD34
A number of non-malignant diseases can be cured or ameliorated by allogeneic hematopoietic stem cell transplantation, such as bone marrow failure syndromes, immunodeficiencies or inborn errors of metabolism. 1 Suitable family donors can be found for up to 30% of such patients, and despite large registries of unrelated donors or cord blood samples, the search for a matched donor remains unsuccessful in a significant number of patients. Safe The CD34 + cell population contains hematopoietic stem and progenitor cells which are able to reconstitute hematopoiesis in the autologous as well as in the allogeneic setting.
2,3 CD34 + cell selection reduces the content of T cells in an apheresis product such that severe GVHD is prevented even in transplants from HLA-mismatched donors. The increased risk of non-engraftment which would be expected due to both the mismatching and the T cell depletion has not been observed. 4, 5 Successful CD34-enriched BMT from haploidentical donors has been reported for adult patients and children. [6] [7] [8] We have transplanted six children with otherwise fatal non-malignant diseases and, lacking a better HLA-matched donor, have used the mother or father as donors.
Patients and methods

Patients
Six children received CD34-enriched peripheral stem cell transplants for non-malignant disorders with an otherwise fatal prognosis (see Table 1 ). In all cases, a matched family donor or a matched unrelated donor could not be found in due time. Patient 1 suffered from the late onset variant of Krabbe's disease (globoid cell leukodystrophy), patient 5 from the infantile form of the same illness which was diagnosed before severe neurologic manifestations because a first son of these parents had died from it. Patients 2 and 6 had familial hemophagocytic lymphohistiocytosis (HLH) and were transplanted after one life-threatening relapse each, one involving the CNS. Patient 3 suffered from congenital megakaryocytic thrombocytopenia (CAMT) with incipient marrow failure. She is included in a series of patients with CAMT published elsewhere. 9 Patient 4 had very severe aplastic anemia (SAA) refractory to immunosuppressive treatment; her course has been described before. 10 The parents of all patients were aware of the experimental nature of the treatment and gave their informed consent to it. 
Donors and grafts
Since neither a related nor an unrelated matched donor was available, we considered a haploidentical transplant. Donors were the mother in patients 1, 2 and 3 and the father in patients 5 and 6. Both parents of patient 4 had contraindications for marrow or stem cell harvest; thus, a paternal uncle, HLA-genotypically identical to the patient's father, donated his peripheral stem cells. HLA testing for loci A, B (and C in three cases), DRB1 and DQB1 was performed by PCR-SSP. The donor-recipient constellations are given in Table 2 . Due to HLA homozygosity, some mismatches were in the GVH or HVG direction only. Between patient 5 and his father, all three mismatches were in the HVG direction (resulting in a low risk of GVHD). After informed consent, all donors underwent one filgrastim-stimulated peripheral stem cell collection and the donor for patient 4 was stimulated twice and had three aphereses done. All apheresis products were T cell depleted by magnetic positive selection of CD34 + cells using the CliniMACS sorting device (Miltenyi Biotec, Bergisch-Gladbach, Germany) and were cryopreserved. 4 The median cell doses transplanted were 16.7 ϫ 10 6 CD34 + cells/kg (range 5.4-50.0) and 1.2 ϫ 10 4 CD3 + cells/kg (range 0.5-2.8). 
Transplantation procedure and engraftment
All patients were prepared using myeloablative and immunosuppressive regimens. Patient 4 who had SAA was treated with total lymphoid irradiation of 8 Gy, fludarabine 180 mg/m 2 , cyclophosphamide 200 mg/kg and OKT3. 10 All other patients were given busulfan 16 mg/kg (20 mg/kg if Ͻ2 years of age), thiotepa 300 mg/m 2 , cyclophosphamide 200 mg/kg and OKT3 from day −3 until day 10. Infusion of the thawed CD34
+ cells was tolerated without any sideeffects. No additional drugs were given for prophylaxis of GVHD. Granulocyte engraftment was observed in all patients, with a median time to reach Ͼ0.5 neutrophils/nl of 11 days (9-19). Platelet counts over 50/nl were reached in five children after 12 days (10-25); one child receiving prolonged antiviral treatment did not pass this threshold. Details are given in Table 3 .
Outcome
Acute graft-versus-host disease occurred in three patients (Nos 2, 3 and 4). It was restricted to skin stage 2-3, thus overall grade I, and responded to steroids. At the time of writing, two children are suffering from bronchiolitis oblit- + cell counts and normal T cell function as judged by reactivity to mitogens and recall antigens. Four patients had reduced T cell numbers and lower than normal results on at least one of the functional tests.
Patient 1 died on day +41 of multiorgan failure following a generalized herpes simplex virus infection unresponsive to aciclovir, cidofovir and foscavir. The other patients showed sustained engraftment. Patient 4 died 8 months after BMT from fulminant hepatic failure during an acute adenovirus infection while on cyclosporin treatment for recurrent GVHD of the skin. The remaining four patients have now been followed for 13, 15, 25 and 26 months. Neither child with HLH has relapsed, the girl with CAMT has normal platelet counts and the child with infantile Krabbe's disease shows positive neuromuscular development, although retarded for his age, while the expected course of the disease and the observed fate of his brother are that of progressive neuromotor degeneration. One child with GVHD of the skin is on decreasing prednisone doses. She also suffers from bronchiolitis obliterans and recurrent upper respiratory tract infections, both of which have improved considerably after intermittent treatment with high-dose methylprednisolone.
Discussion
Haploidentical BMT is associated with the risks of nonengraftment and GVHD. If the grafts are T cell depleted, GVHD can be prevented, but non-engraftment becomes even more likely. With the use of peripheral stem cell collection, larger numbers of stem cells can be made available for transplantation. It has been shown that the risk of graft failure can be overcome if high numbers of stem cells are given. 11 Among all diseases for which allogeneic BMT is undertaken, metabolic disorders and severe aplastic anemia are known to carry a particular risk for non-engraftment. Thus, haploidentical allogeneic BMT from a parental donor in a patient with non-malignant disease carries all those risks. We have treated six children in this setting. All of them have engrafted promptly. Only three have developed acute GVHD, none exceeding grade I. This is an encouraging observation, which has only rarely been reported in similar circumstances.
A large multicenter study of allogeneic BMT in children with Hurler's syndrome included 26 T cell-depleted grafts from haploidentical donors. Complete engraftment occurred in 16/26 (62%), acute GVHD Ͼ grade I in 12/22 assessable children (55%). The actuarial probability of survival at 5 years was 53% for the haploidentical transplant patients.
Numbers of transplanted CD34
+ or CD3 + cells are not given in this report. These multicenter results have in common that one-third of all haploidentical transplants did not engraft and that despite T cell depletion plus pharmacological GVHD prophylaxis in the majority of patients, acute GVDH of more than grade I occurred in 20 to 50%. Our patients, albeit small in number, seem to have avoided those risks: all engrafted with no GVHD grades II-IV. Comparable results are found in one meeting report from the Pediatric Oncology group of Tubingen, Germany, on 17 patients with non-malignant diseases who were transplanted with CD34
+ -selected cells from either matched unrelated or haploidentical family donors. The haploidentical grafts contained 28 ϫ 10 6 CD34 + cells/kg. The following data refer to the whole group of 17 children with both kinds of donors: CD3 + cell number 0.9 ϫ 10 4 /kg, engraftment rate 14/17 (82%), GVHD Ͼ grade I 1/17 (6%), causes of infectious death (1 ×) and non-engraftment (2 ×), 3-year event-free survival 82%. 13 Such results give rise to the hope that allogeneic BMT from haploidentical donors can also be used for patients with metabolic diseases, severe aplastic anemia, other bone marrow failure syndromes and histiocytic disorders such as familial hemophagocytic lymphohistiocytosis. T cell depletion can apparently prevent severe GVHD. From the data cited, the threshold seems to be about 1-2 ϫ 10 4 CD3
+ cells/kg. The risk of non-engraftment resulting from efficient T cell depletion must be overcome by large doses of stem cells, preferably Ͼ10 ϫ 10 6 CD34 + cells/kg. To reach such numbers, the method of CD34
+ selection must furnish cell preparations with a high purity and with a good recovery rate. The immunomagnetic method used by Lang et al 13 and by ourselves allows such numbers to be reached while selecting CD34
+ cells with 97% purity and recovering 71% of the cells. 4 Other methods of CD34 + selection may be similarly efficient.
The second important factor for engraftment is the conditioning regimen. In all diseases with untreated normal or even hypercellular hemopoiesis (eg thalassemia) this regimen should be myeloablative, to create at least some space for the graft, and very immunosuppressive at the same time. For this reason, we and others 13 have included fludarabine and OKT3 in the pretransplant regimen. Other authors also use strongly immunosuppressive regimens. In patients with leukemia who are already immunosuppressed by their preceding antileukemic treatment, Aversa et al 6 have used TBI, cyclophosphamide, thiotepa and ALG. Elhasid and others gave fludarabine plus ALG to a patient with Fanconi anemia before the second haploidentical graft from the father after failure of a first graft from the mother. They reported rapid and sustained engraftment and no acute GVHD. 14 The two main clinical problems after haploidentical BMT are GVHD and fatal infections. Rates of acute GVHD differ in the reports. Even patients who were given additional GVHD prophylaxis with cyclosporin, MTX, tacrolimus or steroids experienced grades II-IV GVHD more often 7, 12 than others in whom T cell depletion and ATG or OKT3 in the pretransplant regimen were the only preventive measures against GVHD (Ref . 13 and this report) . Is the number of T cells transplanted the decisive factor? In Kato et al's series, 7 patients received mean T cell doses of 6-12 ϫ 10 4 /kg; the use of ATG, steroids, MTX and cyclosporin was variable. Twenty-one percent of the patients developed GVHD Ͼ grade I, but the severity of GVHD did not correlate with the T cell dose. The leukemic patients reported by Aversa et al 6 were given a mean of 2.7 ϫ 10 4 /kg of CD3 + cells; no acute or chronic GVHD developed. Matsuda et al 15 have treated four children with malignancies and one with Fanconi's anemia with haploidentical CD34
+ -selected stem cell transplantation and gave a median of 2.3 ϫ 10 4 CD3 + cells/kg; no acute GVHD Ͼ grade I was seen. 15 We transplanted less than 2 ϫ 10 4 /kg of CD3 + cells in all but one patient. Lang et al 13 gave a mean of 0.9 ϫ 10 4 CD3 + /kg. In both series of patients, no GVHD Ͼ grade I was observed, while engraftment was prompt in almost all cases. We should therefore favor a limit of 2 ϫ 10 4 CD3 + cells/kg. This may be particularly necessary in patients with non-malignant diseases, because they are not pre-immunosuppressed by anti-cancer therapy, and because patients with diseases such as SAA or histiocytic disorders are likely to undergo BMT with activated cytokine systems which increases the risk of developing acute GVHD.
The second problem is a delayed immunologic recovery, resulting in life-threatening infections from viruses, fungi or bacteria after CD34
+ -selected stem cell transplantation. Most authors report severe and often fatal infections in these patients. Infectious deaths occurred in 38% of Kato's patients, 7 in 11/43 (32%) of Aversa's patients, 6 2/6 (33%) of our own patients and in 1/17 children (33%) in the series of Lang et al. 13 Klingebiel et al 8 have found that the speed of immunologic reconstitution depends on CD34 + cell dose; it was more rapid if Ͼ20 ϫ 10 6 CD34 + cells/kg had been given. Post-transplant immunosuppressive treatment for GVHD will further prolong recovery of the T cell system. Therefore, any grade of GVHD should be avoided with a view to keeping the risk of infectious death as low as possible. Furthermore, it is difficult to reach high CD34 + cell doses per kg in older children. The fact that, of our six patients, both of those who died from infections were 10 years or older may not be coincidental.
In conclusion, CD34 + selection allows stem cell transplantation from mismatched donors, even from parents, in children with non-malignant diseases. Engraftment occurs promptly and severe GVHD can be prevented. A low T cell threshold in the graft and avoidance of post-transplant immunosuppressive therapy seem to be important. The most frequent cause of death is infection from viruses or fungi. Immunological studies to identify patients at risk, and pre-emptive treatment strategies according to those for CMV reactivation or using specific T cell clones are needed to reduce this risk. At present, this type of transplantation is still an experimental procedure which requires more patients and a longer follow-up before being judged.
